Reshaping the Treatment Landscape in the Department of Veteran Affairs: Immunotherapy in Non-Melanoma Skin Cancer
Risk Assessment and the Role of Immunotherapy in Patients with cSCC

Questions marked with a * are required
Contact Information
Which of the following can be used for assessing risk for cSCC recurrence, metastasis or death?
Cemiplimab may be considered in patients who
Powered by QuestionPro